Drug Trial Radar · NCT06009991
The Dose Range of Remimazolam Besylate in Different Age Groups
Last checked: Nov 20, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,876
Planned (sponsor's estimate)
Start
Jul 17, 2023
Primary completion
Sep 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Renmin Hospital of Wuhan University; Wuhan University; The General Hospital of Central Theater Command; Taihe Hospital; Yichang Central People's Hospital; Jingzhou Central Hospital; Beijing Shijitan Hospital, Capital Medical University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; First Affiliated Hospital of Fujian Medical University; Tianjin Nankai Hospital; Sichuan Provincial People's Hospital; Shanxi Bethune Hospital
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, parallel, controlled clinical study of patients at different ages underwent elective non-cardiac surgery under general anesthesia. The aim of this study is to explore the dose range of remimazolam besylate for patients at different ages, to provide guidance for anesthesia induction and maintenance of remimazolam besylate. And to investigate the incidence of perioperative hypotension and postoperative related organ dysfunction in patients received total intravenous anesthesia with remimazolam besylate, compared with propofol.
Conditions
- Remimazolam
- Anesthesia
Interventions
Remimazolam besylateDrug
Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need). Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).
PropofolDrug
Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance. Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of intraoperative hypotensionTime frame: Operation 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ongji Hospital, Tongji Medical College, Huazhong Science and Technology University
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.